ReviewDermatology and therapy2026
The Importance of Achieving High Treatment Targets in Atopic Dermatitis: A Narrative Review.
Review in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is associated with a significant physical, psychological, social and economic burden and a decreased quality of life. There is a relationship between disease burden and the level of disease severity and control. The burden of AD largely depends on skin lesions, itch and sleep disturbances, although other aspects also play a role. Even though treat-to-target approaches have been proposed for AD in recent years, studies showed that many patients with AD continue to perceive disease burden despite the achievement of the established treatment targets. This prompted the conception of the Aiming High in Eczema/Atopic Dermatitis (AHEAD) recommendations, which included novel optimal targets for both clinician- and patient-reported outcomes, the achievement of which is defined as minimal disease activity or MDA. This narrative review appraises studies that show that the achievement of elevated treatment targets results in multiple benefits. Aiming high helps to achieve more in patients with AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.